Skip to content
Clinical Trials – home

Pantoprazole Sodium Sesquihydrate: A Comprehensive Guide for Patients

1 / 2
trials open to patients / all trials
3+
Countries

In short

This article explores the use of Pantoprazole Sodium Sesquihydrate in clinical trials, focusing on bioequivalence and bioavailability studies. These studies compare different formulations of pantoprazole, sometimes in combination with acetylsalicylic acid (ASA), under various conditions. The trials aim to assess how well generic versions of the drug compare to brand-name versions, and how food intake affects drug absorption. Understanding these aspects is crucial for ensuring the effectiveness and safety of pantoprazole in treating conditions such as ulcers and acid reflux.

At a glance

Study Types
Bioequivalence and bioavailability studies
Drug Formulations
Pantoprazole Sodium Sesquihydrate (40 mg), Fixed-dose combination of ASA (100 mg) and Pantoprazole (20 mg)
Study Conditions
Fasting and fed states
Study Design
Open-label, randomized, crossover studies
Primary Outcomes
Pharmacokinetic parameters (Cmax, Tmax, AUC, half-life)
Secondary Outcomes
Tolerability assessment (adverse events, lab tests, vital signs, ECG)
Comparisons
Generic formulations vs. brand-name products (e.g., Protonix, Protium)
Target Conditions
Ulcers (duodenal and gastric), acid-related disorders

What is Pantoprazole?

Pantoprazole Sodium Sesquihydrate, commonly known as pantoprazole, is a medication used to treat various gastrointestinal conditions. It belongs to a class of drugs called proton pump inhibitors (PPIs), which work by reducing stomach acid production. Pantoprazole is available under different brand names, including Protonix® and Protium®.

Uses of Pantoprazole

Pantoprazole is primarily used to treat the following conditions:

  • Gastric and duodenal ulcers: These are sores that develop in the lining of the stomach or the first part of the small intestine (duodenum).
  • Gastroesophageal reflux disease (GERD): A condition where stomach acid frequently flows back into the esophagus, causing heartburn and other symptoms.
  • Erosive esophagitis: Inflammation and damage to the esophagus caused by stomach acid.
  • Zollinger-Ellison syndrome: A rare condition that causes tumors in the pancreas or duodenum, leading to excessive stomach acid production.

Available Formulations

Pantoprazole is available in various formulations, including:

  • Delayed-release tablets: These tablets are designed to release the medication in the small intestine rather than the stomach, ensuring better absorption and effectiveness. They are available in 20 mg and 40 mg strengths.
  • Gastro-resistant tablets: Similar to delayed-release tablets, these are designed to resist stomach acid and release the medication in the intestine.
  • Fixed-dose combination capsules: In some cases, pantoprazole is combined with other medications, such as acetylsalicylic acid (ASA), in a single capsule for convenient administration.

How Pantoprazole Works

Pantoprazole works by blocking the proton pumps in the stomach lining. These pumps are responsible for producing stomach acid. By inhibiting these pumps, pantoprazole reduces the amount of acid produced in the stomach, which helps alleviate symptoms and promote healing of damaged tissues in the digestive tract.

Dosage and Administration

The dosage of pantoprazole varies depending on the condition being treated and the specific formulation used. Some general guidelines include:

  • For most conditions, a common dose is 40 mg once daily.
  • In some cases, lower doses of 20 mg may be used, especially for maintenance therapy.
  • Pantoprazole is typically taken orally with or without food, depending on the specific formulation and instructions provided by your healthcare provider.
  • It's important to take pantoprazole exactly as prescribed and not to adjust the dose without consulting your doctor.

Bioequivalence Studies

Several studies have been conducted to compare different formulations of pantoprazole and ensure they are bioequivalent (meaning they have the same effect in the body). These studies help ensure that generic versions of the medication are as effective as brand-name versions. Key findings from these studies include:

  • Comparisons between different manufacturers' versions of pantoprazole 40 mg delayed-release tablets showed similar effectiveness.
  • Studies were conducted under both fasting and fed conditions to ensure the medication works effectively regardless of when it's taken in relation to meals.
  • Fixed-dose combination capsules containing pantoprazole and acetylsalicylic acid (ASA) were also studied to ensure proper absorption of both medications when taken together.

Potential Side Effects and Tolerability

While pantoprazole is generally well-tolerated, like all medications, it can cause side effects in some people. Common side effects may include:

  • Headache
  • Nausea
  • Diarrhea
  • Stomach pain
  • Dizziness

Studies have been conducted to assess the tolerability of pantoprazole, including when combined with other medications like ASA. These studies monitored for adverse events, conducted laboratory tests, and checked vital signs and electrocardiograms (ECGs) to ensure the medication's safety.

It's important to discuss any side effects or concerns with your healthcare provider. They can provide personalized advice and determine if pantoprazole is the right medication for your specific condition.

Questions people often ask

Conditions where Pantoprazole Sodium Sesquihydrate is being studied

Each condition opens its own overview and trial list

Trials with Pantoprazole Sodium Sesquihydrate

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).